SIBP-A16 not checked
Shanghai Institute Of Biological Products
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants in the placebo group will be assigned to four dose cohorts, and they will receive one dose of Placebo via intramuscular injection.”In the company’s words, NCT07363837 on ClinicalTrials.gov
- Tested for
- Respiratory Syncytial Virus (RSV)
- Main trialPhase 1/2
- “This trial employs a randomized, double-blind, placebo/positive control, and dose-finding design to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of SIBP-A16 injection in premature and term infants.”In the company’s words, NCT07363837 on ClinicalTrials.gov
Other drugs for Respiratory Syncytial Virus (RSV)
- RSVPreF3 OA vaccineGSK · Phase 3
- Human interferon α1b InhalationKexing Biopharm Co., Ltd. · Phase 3
- ABRYSVOPfizer · Phase 3
- ZiresovirShanghai Ark Biopharmaceutical Co., Ltd. · Phase 2/3
- S-337395Shionogi · Phase 2
- ZelicapavirEnanta Pharmaceuticals, Inc · Phase 2
Coming up1
- 31 Mar 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | 31 Mar 2027 | Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026